Current Diagnostic and Therapeutic Approaches to Patients with Acquired von Willebrand Syndrome: A 2013 Update

Augusto B. Federici; Ulrich Budde; Giancarlo Castaman; Jacob H. Rand; Andreas Tiede

doi:10.1055/s-0033-1334867

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2013; 39(02): 191-201
DOI: 10.1055/s-0033-1334867

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Current Diagnostic and Therapeutic Approaches to Patients with Acquired von Willebrand Syndrome: A 2013 Update

Augusto B. Federici

¹Hematology and Transfusion Medicine, L. SACCO University Hospital, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

,

Ulrich Budde

²Haemostaseology Medilys Laborgesellschaft mbH, Asklepios Klinil Altona, Hamburg, Germany

,

Giancarlo Castaman

³Division of Hematology, San Bortolo Hospital, Vicenza, Italy

,

Jacob H. Rand

⁴Hematology Laboratory, Department of Pathology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York

,

Andreas Tiede

⁵Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

› Institutsangaben

Abstract

Acquired von Willebrand syndrome (AVWS) is an acquired bleeding disorder, first reported in 1968, with clinical and laboratory features similar to inherited von Willebrand disease. This rare bleeding disorder occurs mainly in patients with underlying lymphoproliferative, cardiovascular, myeloproliferative, and immunologic disorders. In contrast to acquired hemophilia A, AVWS is rarely associated with measurable anti-von Willebrand factor inhibitors. In most instances, AVWS is identified because of bleeding complications: in fact, more than 80% of the patients with this syndrome are active bleeders. Recurrent bleeding episodes occur in approximately 20 to 33% of patients with AVWS, especially following major trauma and surgery. Because of the heterogeneous mechanisms of AVWS, more than one therapeutic approach is often required to prevent or treat acute bleedings. Remission from some forms of AVWS can be obtained when the underlying disorders are treated.

Keywords

acquired von Willebrand syndrome - inhibitors - lymphoproliferative diseases - cardiovascular diseases - thrombocythemia - autoimmune conditions

Volltext

Referenzen

References
1 Simone JV, Cornet JA, Abildgaard CF. Acquired von Willebrand's syndrome in systemic lupus erythematosus. Blood 1968; 31 (6) 806-812
2 Ingram GIC, Kingston PJ, Leslie J, Bowie EJW. Four cases of acquired von Willebrand's syndrome. Br J Haematol 1971; 21 (2) 189-199
3 Mohri H, Motomura S, Kanamori H , et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91 (10) 3623-3629
4 Mannucci PM, Lombardi R, Bader R , et al. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood 1984; 64 (3) 614-621
5 Jakway JL. Acquired von Willebrand's disease in malignancy. Semin Thromb Hemost 1992; 18 (4) 434-439
6 Rinder MR, Richard RE, Rinder HM. Acquired von Willebrand's disease: a concise review. Am J Hematol 1997; 54 (2) 139-145
7 Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998; 92 (8) 2707-2711
8 Nitu-Whalley IC, Lee CA. Acquired von Willebrand syndrome—report of 10 cases and review of the literature. Haemophilia 1999; 5 (5) 318-326
9 Veyradier A, Jenkins CSP, Fressinaud E, Meyer D. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost 2000; 84 (2) 175-182
10 Federici AB, Rand JH, Bucciarelli P , et al; Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84 (2) 345-349
11 Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001; 14 (2) 401-436
12 Budde U, Bergmann F, Michiels JJ. Acquired von Willebrand syndrome: experience from 2 years in a single laboratory compared with data from the literature and an international registry. Semin Thromb Hemost 2002; 28 (2) 227-238
13 Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand's syndrome: a single institution experience. Am J Hematol 2003; 72 (4) 243-247
14 Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006; 43 (1) (Suppl. 01) S48-S58
15 Tiede A, Priesack J, Werwitzke S , et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost 2008; 6 (4) 569-576
16 Federici AB. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?. J Thromb Haemost 2008; 6 (4) 565-568
17 Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117 (25) 6777-6785
18 Giannini S, Solimando M, Fierro T, Baronciani L, Federici AB, Gresele P. Acquired von Willebrand syndrome type 2A in a JAK2-positive essential thrombocythaemia-affected member of a large von Willebrand disease family with a novel autosomal dominant A1716P mutation. Thromb Haemost 2011; 105 (5) 921-924
19 van Genderen PJ, Boertjes RC, van Mourik JA. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome. Thromb Haemost 1998; 80 (3) 495-498
20 Haberichter SL, Castaman G, Budde U , et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008; 111 (10) 4979-4985
21 Zettervall O, Nilsson IM. Acquired von Willebrand's disease caused by a monoclonal antibody. Acta Med Scand 1978; 204 (6) 521-528
22 Fricke WA, Brinkhous KM, Garris JB, Roberts HR. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody. Blood 1985; 66 (3) 562-569
23 van Genderen PJJ, Vink T, Michiels JJ, van 't Veer MB, Sixma JJ, van Vliet HH. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood 1994; 84 (10) 3378-3384
24 Stewart MW, Etches WS, Shaw ARE, Gordon PA. vWf inhibitor detection by competitive ELISA. J Immunol Methods 1997; 200 (1–2) 113-119
25 Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia 2003; 9 (3) 303-308
26 Friederich PW, Wever PC, Briët E, Doorenbos CJ, Levi M. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001; 66 (4) 292-294
27 Silberstein LE, Abrahm J, Shattil SJ. The efficacy of intensive plasma exchange in acquired von Willebrand's disease. Transfusion 1987; 27 (3) 234-237
28 Tran-Thang C, Mannucci PM, Schneider P, Federici A, Bachmann F. Profound alterations of the multimeric structure of von Willebrand factor in a patient with malignant lymphoma. Br J Haematol 1985; 61 (2) 307-314
29 Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986; 67 (3) 758-761
30 Heyde EC. Gastrointestinal bleeding in aortic stenosis. N Engl J Med 1958; 259: 196
31 King RM, Pluth JR, Giuliani ER. The association of unexplained bleeding with calcific aortic stenosis. Ann Thorac Surg 1987; 44: 514-516
32 Weinstein M, Ware JA, Troll J, Salzman E. Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate. Blood 1988; 71 (6) 1648-1655
33 Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link?. Lancet 1992; 340 (8810) 35-37
34 Lopes AAB, Maeda NY, Aiello VD, Ebaid M, Bydlowski SP. Abnormal multimeric and oligomeric composition is associated with enhanced endothelial expression of von Willebrand factor in pulmonary hypertension. Chest 1993; 104 (5) 1455-1460
35 Anderson RP, McGrath K, Street A. Reversal of aortic stenosis, bleeding gastrointestinal angiodysplasia, and von Willebrand syndrome by aortic valve replacement. Lancet 1996; 347 (9002) 689-690
36 Knobloch W, Hauser E, Niehues R , et al. Calcifying aortic valve stenosis and cryptogenic gastrointestinal bleeding (Heyde syndrome): report of two cases. Z Kardiol 1999; 88: 448-453
37 Pareti FI, Lattuada A, Bressi C , et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000; 102 (11) 1290-1295
38 Rauch R, Budde U, Girisch M, Klinge J, Hofbeck M. Acquired von Willebrand disease in an infant. Resolution by interventional occlusion of patent ductus arteriosus. Thromb Res 2001; 102 (5) 407-409
39 Veyradier A, Balian A, Wolf M , et al. Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract. Gastroenterology 2001; 120 (2) 346-353
40 Arslan MT, Ozyurek R, Kavakli K , et al. Frequency of acquired von Willebrand's disease in children with congenital heart disease. Acta Cardiol 2007; 62 (4) 403-408
41 Vincentelli A, Susen S, Le Tourneau T , et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349 (4) 343-349
42 Velik-Salchner C, Eschertzhuber S, Streif W , et al. Acquired von Willbrand syndrome in cardiac patients. J Thorac Vasc Anesth 2007;
43 Geisen U, Heilmann C, Beyersdorf F , et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg 2008; 33 (4) 679-684
44 Sánchez-Luceros A, Meschengieser SS, Woods AI , et al. Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution. Haematologica 2002; 87 (3) 264-270
45 Budde U, Schaefer G, Mueller N , et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984; 64 (5) 981-985
46 Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82 (6) 1749-1757
47 Van Genderen PJ, Michiels JJ. Erythromelalgic, thrombotic and hemorrhagic thrombocythemia. Presse Med 1994; 23: 73-77
48 Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006; 32 (6) 589-604
49 Fabris F, Casonato A, Grazia del Ben M, De Marco L, Girolami A. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol 1986; 63 (1) 75-83
50 van Genderen PJJ, Budde U, Michiels JJ, van Strik R, van Vliet HH. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol 1996; 93 (4) 962-965
51 Casonato A, Fabris F, Zancan L, Girolami A. Acquired type I von Willebrand's disease in a patient with essential thrombocytosis. Acta Haematol 1986; 75 (3) 188-189
52 Budde U, Dent JA, Berkowitz SD, Ruggeri ZM, Zimmerman TS. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1986; 68 (6) 1213-1217
53 Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 2008; 111 (2) 651-657
54 Bangerter M, Güthner C, Beneke H, Hildebrand A, Grünewald M, Griesshammer M. Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies. Eur J Haematol 2000; 65 (3) 165-169
55 Ruggeri M, Rodeghiero F, Tosetto A , et al; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Chronic Myeloproliferative Diseases Working Party. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 2008; 111 (2) 666-671
56 Finazzi G, Budde U, Michiels JJ. Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. Leuk Lymphoma 1996; 22 (Suppl. 01) 71-78
57 Coppes MJ, Zandvoort SWH, Sparling CR, Poon AO, Weitzman S, Blanchette VS. Acquired von Willebrand disease in Wilms' tumor patients. J Clin Oncol 1992; 10 (3) 422-427
58 Baxter PA, Nuchtern JG, Guillerman RP , et al. Acquired von Willebrand syndrome and Wilms tumor: not always benign. Pediatr Blood Cancer 2009; 52 (3) 392-394
59 Hong S, Lee J, Chi H , et al. Systemic lupus erythematosus complicated by acquired von Willebrand's syndrome. Lupus 2008; 17 (9) 846-848
60 Kreuz W, Linde R, Funk M , et al. Induction of von Willebrand disease type I by valproic acid. Lancet 1990; 335 (8701) 1350-1351
61 Strauss RG, Stump DC, Henriksen RA. Hydroxyethyl starch accentuates von Willebrand's disease. Transfusion 1985; 25 (3) 235-237
62 Dalton RG, Dewar MS, Savidge GF , et al. Hypothyroidism as a cause of acquired von Willebrand's disease. Lancet 1987; 1 (8540) 1007-1009
63 Benson PJ, Peterson LC, Hasegawa DK, Smith II CM. Abnormality of von Willebrand factor in patients with hemoglobin E-β (0) thalassemia. Am J Clin Pathol 1990; 93 (3) 395-399
64 Koenig S, Gerstner T, Keller A, Teich M, Longin E, Dempfle CE. High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Blood Coagul Fibrinolysis 2008; 19 (5) 375-382
65 Eberl W, Budde U, Bentele K , et al. Acquired von Willebrand syndrome as side effect of valproic acid therapy in children is rare. Hamostaseologie 2009; 29 (2) 137-142
66 Franchini M, Zugni C, Veneri D , et al. High prevalence of acquired von Willebrand's syndrome in patients with thyroid diseases undergoing thyroid surgery. Haematologica 2004; 89 (11) 1341-1346
67 Gralnick HR, McKeown LP, Williams SB, Shafer BC, Pierce L. Plasma and platelet von Willebrand factor defects in uremia. Am J Med 1988; 85 (6) 806-810
68 Pasa S, Altintas A, Cil T, Danis R, Ayyildiz O, Muftuoglu E. A case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximab. J Thromb Thrombolysis 2009; 27 (2) 220-222
69 Kos CA, Ward JE, Malek K , et al. Association of acquired von Willebrand syndrome with AL amyloidosis. Am J Hematol 2007; 82 (5) 363-367
70 Haj MA, Murch N, Bowen DJ , et al. Cefotaxime as the potential cause of transient acquired von Willebrand syndrome. Eur J Haematol 2006; 76 (5) 440-443
71 Mühlhausen C, Schneppenheim R, Budde U , et al. Decreased plasma concentration of von Willebrand factor antigen (VWF:Ag) in patients with glycogen storage disease type Ia. J Inherit Metab Dis 2005; 28 (6) 945-950
72 Sokol L, Stueben ET, Jaikishen JP, Lamarche MB. Turner syndrome associated with acquired von Willebrand disease, primary biliary cirrhosis, and inflammatory bowel disease. Am J Hematol 2002; 70 (3) 257-259